Medicus Pharma [MDPLD] vs Merck & Co [MRK] Detailed Stock Comparison

Medicus Pharma Ltd.

NASDAQ
Loading...

Merck & Co., Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Medicus Pharma Ltd. wins in 2 metrics, Merck & Co., Inc. wins in 9 metrics, with 1 ties. Merck & Co., Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Medicus Pharma Ltd. Merck & Co., Inc. Better
P/E Ratio (TTM) -1.47 15.74 Merck & Co., Inc.
Price-to-Book Ratio 3.90 5.39 Medicus Pharma Ltd.
Debt-to-Equity Ratio 0.10 95.96 Medicus Pharma Ltd.
PEG Ratio N/A -0.82 N/A
EV/EBITDA 0.00 10.97 Tie
Profit Margin (TTM) 0.00% 28.08% Merck & Co., Inc.
Operating Margin (TTM) 0.00% 32.77% Merck & Co., Inc.
EBITDA Margin (TTM) N/A 32.77% N/A
Return on Equity -841.91% 36.88% Merck & Co., Inc.
Return on Assets (TTM) -358.37% 12.04% Merck & Co., Inc.
Free Cash Flow (TTM) $-4.16M $12.36B Merck & Co., Inc.
Dividend Yield N/A 2.91% N/A
1-Year Return N/A 45.70% N/A
Price-to-Sales Ratio (TTM) N/A 4.35 N/A
Enterprise Value $0 $319.41B Merck & Co., Inc.
EV/Revenue Ratio N/A 4.91 N/A
Gross Profit Margin (TTM) N/A 66.15% N/A
Revenue per Share (TTM) $0 $26 Merck & Co., Inc.
Earnings per Share (Diluted) $-2.54 $7.28 Merck & Co., Inc.
Beta (Stock Volatility) N/A 0.28 N/A
Short % of Float N/A 1.12% N/A

Medicus Pharma Ltd. vs Merck & Co., Inc. Stock Performance Analysis

Loading Price Chart...

MDPLD
MRK

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Medicus Pharma Ltd.1.78%0.00%0.00%0.00%0.00%0.00%
Merck & Co., Inc.-3.49%-3.87%3.16%-0.46%14.60%7.94%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Medicus Pharma Ltd.N/AN/AN/AN/AN/AN/A
Merck & Co., Inc.45.70%8.90%55.40%123.23%252.74%262.85%

Performance & Financial Health Analysis: Medicus Pharma Ltd. vs Merck & Co., Inc.

MetricMDPLDMRK
Market Information
Market Cap iN/A$283.10B
Market Cap CategoryN/AMega cap
10 Day Avg. Volume i20,0919,732,998
90 Day Avg. Volume i36,7129,710,049
Last Close$2.86$114.90
52 Week Range$1.80 - $6.00$76.66 - $125.14
% from 52W High-52.33%-8.18%
All-Time High$3.00 (Jan 24, 2025)$134.63 (Jun 24, 2024)
% from All-Time High-4.67%-14.65%
Growth Metrics
Quarterly Revenue GrowthN/A0.05%
Quarterly Earnings GrowthN/A-0.21%
Financial Health
Profit Margin (TTM) i0.00%0.28%
Operating Margin (TTM) i0.00%0.33%
Return on Equity (TTM) i-8.42%0.37%
Debt to Equity (MRQ) i0.1095.96
Cash & Liquidity
Book Value per Share (MRQ)$0.73$21.26
Cash per Share (MRQ)N/A$5.89
Operating Cash Flow (TTM) i$-4,987,008$16.47B
Levered Free Cash Flow (TTM) i$-6,784,140$11.89B
Dividends
Last 12-Month Dividend Yield iN/A2.91%
Last 12-Month Dividend iN/A$3.32

Valuation & Enterprise Metrics Analysis: Medicus Pharma Ltd. vs Merck & Co., Inc.

MetricMDPLD (Mar 31, 2025)MRK (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-1.4715.74
Forward P/E iN/A11.80
PEG Ratio iN/A-0.82
Price to Sales (TTM) iN/A4.35
Price to Book (MRQ) i3.905.39
Market Capitalization
Market Capitalization i$22.45M$283.10B
Enterprise Value i$0$319.41B
Enterprise Value Metrics
Enterprise to Revenue iN/A4.91
Enterprise to EBITDA i0.0010.97
Risk & Other Metrics
Beta iN/A0.28
Book Value per Share (MRQ) i$0.73$21.26

Financial Statements Comparison: Medicus Pharma Ltd. vs Merck & Co., Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMDPLD (2023)MRK (2025)
Revenue/Sales i065.01B
Cost of Goods Sold iN/A16.38B
COGS % of Revenue i-25.2%
Gross Profit iN/A48.63B
Gross Margin i-74.8%
Research & Development i193,57815.79B
Operating Income (EBIT) i-3.01M22.11B
Operating Margin i-34.0%
EBITDA i-6.72M29.11B
EBITDA Margin i-44.8%
Pre-Tax Income i-6.78M21.07B
Pre-Tax Income % of Revenue i-32.4%
Income Tax iN/A2.80B
Income Tax % of Revenue i-4.3%
Net Income (Profit) i-6.78M18.26B
Profit Margin i-28.1%

Balance Sheet & Liquidity Metrics

MetricMDPLD (2023)MRK (2025)
Cash & Equivalents i1.72M14.57B
Total Current Assets i1.89M43.52B
Total Current Assets % of Revenue i-66.9%
Total Current Liabilities i1.09M28.33B
Total Current Liabilities % of Revenue i-43.6%
Long-Term Debt iN/A46.75B
Long-Term Debt % of Revenue i-71.9%
Total Shareholders Equity i805,80052.66B
Retained Earnings i-19.18M73.08B
Retained Earnings % of Revenue i-112.4%
Property, Plant & Equipment iN/A0

Cash Flow Statement Comparison

MetricMDPLD (2023)MRK (2025)
Operating Cash Flow i-4.99M18.49B
Operating Cash Flow % of Revenue i-28.4%
Capital Expenditures iN/AN/A
Free Cash Flow i-4.16M12.36B
FCF Margin i-19.0%
Debt Repayment iN/A-2.50B
Common Stock Repurchase iN/A-5.08B

Short Interest & Institutional Ownership Analysis

MetricMDPLDMRK
Shares Short iN/A27.72M
Short Ratio iN/A2.69
Short % of Float iN/A1.12%
Shares Outstanding i8.08M2.47B
Float Shares iN/A2.47B
% Held by Insiders i55.81%0.06%
% Held by Institutions i0.00%81.44%
% Held by Public i44.19%18.50%

Dividend Analysis & Yield Comparison: Medicus Pharma Ltd. vs Merck & Co., Inc.

MetricMDPLDMRK
Last 12-Month Dividend iN/A$3.32
Last 12-Month Dividend Yield iN/A2.91%
3-Year Avg Annual Dividend iN/A$3.16
3-Year Avg Dividend Yield iN/A0.77%
3-Year Total Dividends iN/A$9.48
Ex-Dividend DateN/AMar 16, 2026